In focus · trending topic

Phase 2 Results

1 stories · following the connections

Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder

By Nasdaq OMXFeb 16, 2017, 12:02 PM UTC